40
Participants
Start Date
February 29, 2012
Primary Completion Date
October 31, 2013
Study Completion Date
November 30, 2013
Rivaroxaban (Xarelto, BAY59-7939)
15 mg twice daily for 21 days, followed by 15 mg once daily
Unfractionated heparin
To be adjusted to maintain the activated partial thromboplastin time (aPTT) prolongation (1.5 to 2.5 times the control)
Warfarin
To be adjusted on the basis of prothrombin time-international normalized ratio (PT-INR) values target range (1.5 to 2.5)
Nagoya
Toyoake
Aomori
Chiba
Sakura
Kurume
Maebashi
Sapporo
Kahoku-gun
Kanazawa
Yokohama
Kumamoto
Tsu
Matsumoto
Suwa
Niigata
Osaka
Osaka
Osaka
Sayama
Suita
Saga
Shizuoka
Shimotsuke
Bunkyo-ku
Bunkyo-ku
Chuoku
Itabashi-ku
Meguro-ku
Shinagawa
Shinjuku-ku
Lead Sponsor
Janssen Research & Development, LLC
INDUSTRY
Bayer
INDUSTRY